Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis

Table 1 Worst evolution (negative events altogether evaluated) and hepatocellular carcinoma incidence in interferon treated patients n (%)

	Worst evolution	HCC
NR	13/22 (59.0)	7/22 (31.8)
SR	3/11 (27.2)b	3/11 (27.2)
RR	7/18 (38.8)b	5/18 (27.7)
Not treated	63/71 (88.7)b	24/71 (33.8)

^bP < 0.01 vs non responder (NR). SR: Sustained responder; RR: Relapse responder; HCC: Hepatocellular carcinoma.

Table 2 Features of the studies on cirrhotic patients

Type study	Follow-up (mo)	IFN (wk)	Sample size	Mean age (yr)	RR	Ref.
RCT	24-86	6 MU tiw (12-24)	T 45/C45	55	-0.4	[31]
NRCT/P	12-71	3 MU tiw (52)	T193/C91	57	-0.1	[32]
NRCT/P	60-84	6 MU tiw (26)	T82/C81	56	2	[33]
NRCT/P	43	3 MU tiw (65)	T103/C59	57	-0.05	[34]
RCT	60	6 MU tiw (18) 3 MU tiw (18)	T38/C23	57	> 1	[35]
P	55	1 MU tiw (12) 3 MU tiw (12) 6 MU tiw (12) 9 MU tiw (12)	T72/C72	58	-0.2	[36]
R	96	3 MU tiw (12)	T52/C71	56	> 1	[19]
P	60	6 MU/mo (4) 3 MU/mo (44)	T41/C30	56	-0.1	[37]
R	96	3 MU tiw (12)	T52/C71	56	> 1	[22]
P	60	3-6 MU tiw plus Ribavirin (2-48)	T1057/C562	56	-0.05	[38]
RCT	45	3 MU tiw (48) (post-resection)	T76/C74	66	> 1	[39]
P	96	6 MU tiw (24-48)	T82/T81	57	-0.04	[40]

RCT: Randomized controlled trial; NRCT: Non randomized controlled trial; P: Prospective; R: Retrospective; IFN: Interferon; T: Patients treated; C: Controls; RR: Relative risk.